Clinical Trial Update: A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ibrutinib with bendamustine and rituximab in relapsed/refractory CLL or SLL has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Ibrutinib (ibrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2020-03-03